Abstract
Mayo Clinic Cardiac Catheterization Laboratory’s role in understanding the pathophysiology, establishing the diagnosis, predicting the prognosis, and advancing treatment of coronary endothelial dysfunction has been, and in fact remains, crucial. Following Robert F. Furchgott’s 1986 historic announcement on the major role of endothelium-derived nitric oxide (NO) in regulation of vascular tone, Mayo Clinic researchers demonstrated that the functional and structural integrity of the vascular endothelium is not only important to maintain balance between circulating endothelium-derived vasodilator and vasoconstrictor molecules but also confers protection against arterial atherosclerosis and thrombosis. Acetylcholine catheter-based evaluation protocol of coronary epicardial and microvascular endothelial function was initiated in 1994 as part of an NIH grant and approved for clinical practice in 1997. In 1994, the Mayo Endothelial Database – world’s current largest invasive database of coronary endothelial and microvascular function assessment – enrolled its first patient. In a series of subsequent cutting-edge high-impact studies between 1997 and 2000, our lab demonstrated the association between coronary endothelial and microvascular dysfunction, myocardial ischemia, and increased risk of severe adverse cardiovascular events. Since 2001, we have investigated new therapeutic options for coronary endothelial dysfunction that either constitute current mainstay clinical therapy for this challenging disease entity, such statins and L-arginine, or cornerstone early studies of potentially promising investigational therapies such as endothelin-1 antagonists and most recently autologous intracoronary CD34+ cell therapy. In 2018, we were among the first to introduce and advance the concept of endothelial dysfunction as a systemic disease with not only cardiac but also numerous extracardiac clinical manifestations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rubanyl GM, Frye RL, Holmes DR Jr, Vanhoutte PM. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol. 1987;9(6):1243–9.
Furchgott RF, Cherry PD, Zawadzki JV, Jothianandan D. Endothelial cells as mediators of vasodilation of arteries. J Cardiovasc Pharmacol. 1984;6(Suppl 2):S336–43.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–6.
Lerman A, Webster MW, Chesebro JH, Edwards WD, Wei CM, Fuster V, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88(6):2923–8.
Badimon L, Badimon JJ, Penny W, Webster MW, Chesebro JH, Fuster V. Endothelium and atherosclerosis. J Hypertens Suppl. 1992;10(2):S43–50.
Nishimura RA, Lerman A, Chesebro JH, Ilstrup DM, Hodge DO, Higano ST, et al. Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound. J Am Coll Cardiol. 1995;26(1):41–9.
Gutiérrez E, Flammer AJ, Lerman LO, Elízaga J, Lerman A, Fernández-Avilés F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34(41):3175–81.
Yoon MH, Reriani M, Mario G, Rihal C, Gulati R, Lennon R, et al. Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol. 2013;168(2):1316–21.
Godo S, Corban MT, Toya T, Gulati R, Lerman LO, Lerman A. Association of coronary microvascular endothelial dysfunction with vulnerable plaque characteristics in early coronary atherosclerosis. EuroIntervention. 2020;16(5):387–94.
Lavi S, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, et al. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart. 2009;95(18):1525–30.
Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96(10):3390–5.
Summers MR, Lerman A, Lennon RJ, Rihal CS, Prasad A. Myocardial ischaemia in patients with coronary endothelial dysfunction: insights from body surface ECG mapping and implications for invasive evaluation of chronic chest pain. Eur Heart J. 2011;32(22):2758–65.
Cassar A, Chareonthaitawee P, Rihal CS, Prasad A, Lennon RJ, Lerman LO, et al. Lack of correlation between noninvasive stress tests and invasive coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease. Circ Cardiovasc Interv. 2009;2(3):237–44.
Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948–54.
Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 2003;107(22):2805–9.
Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21(1):122–8.
Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97(21):2123–8.
Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation. 2010;122(10):958–66.
Corban MT, Lerman LO, Lerman A. Ubiquitous yet unseen: microvascular endothelial dysfunction beyond the heart. Eur Heart J. 2018;39(46):4098–100.
Corban MT, Godo S, Burczak DR, Noseworthy PA, Toya T, Lewis BR, et al. Coronary endothelial dysfunction is associated with increased risk of incident atrial fibrillation. J Am Heart Assoc. 2020;9(8):e014850.
Ahmad A, Corban MT, Toya T, Verbrugge FH, Sara JD, Lerman LO, et al. Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(5):765–72.
Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56(11):845–54.
Reriani M, Flammer AJ, Li J, Prasad M, Rihal C, Prasad A, et al. Microvascular endothelial dysfunction predicts the development of erectile dysfunction in men with coronary atherosclerosis without critical stenoses. Coron Artery Dis. 2014;25(7):552–7.
Corban MT, Duarte-Garcia A, McBane RD, Matteson EL, Lerman LO, Lerman A. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol. 2017;69(18):2317–30.
Prasad M, McBane R, Reriani M, Lerman LO, Lerman A. Coronary endothelial dysfunction is associated with increased risk of venous thromboembolism. Thromb Res. 2016;139:17–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Mayo Foundation for Medical Education and Research, under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lerman, A., Corban, M.T. (2021). Coronary Endothelial and Microvascular Function Testing. In: Holmes Jr., D.R., Frye, R.L., Friedman, P.A., Hagler, D.J., Munger, T.M., Ritman, E.L. (eds) The Mayo Clinic Cardiac Catheterization Laboratory. Springer, Cham. https://doi.org/10.1007/978-3-030-79329-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-79329-6_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-79328-9
Online ISBN: 978-3-030-79329-6
eBook Packages: MedicineMedicine (R0)